Glancy Binkow & Goldberg LLP Announces Class Action Lawsuit on Behalf of Investors of Sanofi Contingent Value Rights

  Glancy Binkow & Goldberg LLP Announces Class Action Lawsuit on Behalf of
  Investors of Sanofi Contingent Value Rights

Business Wire

LOS ANGELES -- January 17, 2014

Glancy Binkow & Goldberg LLP announces that a class action lawsuit has been
filed in the United States District Court for the Southern District of New
York on behalf of a class (the “Class”) comprising all purchasers of the
Contingent Value Rights (“CVRs”) of Sanofi (NASDAQ:GCVRZ) between March 6,
2012 and November 7, 2013, inclusive (the “Class Period”).

A COPY OF THE COMPLAINT IS AVAILABLE FROM THE COURT OR FROM GLANCY BINKOW &
GOLDBERG LLP. PLEASE CONTACT US TOLL-FREE AT 888-773-9224, OR AT 212-682-5340,
OR BY EMAIL TO SHAREHOLDERS@GLANCYLAW.COM TO DISCUSS THIS MATTER. IF YOU
INQUIRE BY EMAIL PLEASE INCLUDE YOUR MAILING ADDRESS, TELEPHONE NUMBER AND
NUMBER OF SHARES PURCHASED.

Sanofi is a global healthcare company engaged in the research, development,
manufacture and marketing of healthcare products, including pharmaceuticals
and vaccines. Sanofi’s multiple sclerosis therapy, Lemtrada™ (alemtuzumab),
has completed two Phase III clinical studies and is under review for U.S. Food
and Drug Administration marketing approval in the U.S. and Europe. The
Complaint alleges that defendants knew or recklessly disregarded but failed to
disclose that:

  *Defendants had materially misrepresented the safety and efficacy of
    Lemtrada in statements to investors and the public.
  *The design of the Lemtrada trials contained high levels of placebo effect
    and observer bias, which tainted the results and lowered the likelihood of
    FDA approval.
  *The company lacked adequate internal controls.
  *Defendants lacked a reasonable basis for their positive statements about
    Lemtrada and its prospects.

On November 8, 2013, a report prepared ahead of a FDA advisory panel meeting
noted “serious and potentially fatal” risks of autoimmune diseases including
“blood disorders, infections and cancer.” The FDA staff did not recommend
approval of Lemtrada “unless substantial clinical benefit exists.” Following
this news, Sanofi CVRs dropped more than 60%, to a closing price of $0.77 per
share on November 8, 2013, on extremely heavy trading volume.

If you are a member of the Class described above, you may move the Court no
later than February 10, 2014, to serve as lead plaintiff; however, you must
meet certain legal requirements If you wish to learn more about this action or
have any questions concerning this announcement or your rights or interests
with respect to these matters, please contact Michael Goldberg, Esquire, of
Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles,
California 90067, Toll-Free at 888-773-9224, or contact Gregory Linkh,
Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd Street, Suite 2920,
New York, New York 10168, at 212-682-5340, by e-mail to
shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com.
If you inquire by email please include your mailing address, telephone number
and number of shares purchased.

This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.

Contact:

Glancy Binkow & Goldberg LLP, Los Angeles, CA
Michael Goldberg, 888-773-9224
or
Glancy Binkow & Goldberg LLP, New York, NY
Gregory Linkh, 212-682-5340 or 888-773-9224
shareholders@glancylaw.com
www.glancylaw.com
 
Press spacebar to pause and continue. Press esc to stop.